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Chemokines and ATP are among the mediators of inﬂammatory sites that can enter the circulation via damaged blood vessels. The
main function of chemokines is leukocyte mobilization, and ATP typically triggers inﬂammasome assembly. IL-1β, a potent
inﬂammasome-dependent cytokine of innate immunity, is essential for pathogen defense. However, excessive IL-1β may cause
life-threatening systemic inﬂammation. Here, we hypothesize that chemokines control ATP-dependent secretion of monocytic
IL-1β. Lipopolysaccharide-primed human monocytic U937 cells were stimulated with the P2X7 agonist BzATP for 30min to
induce IL-1β release. CCL3, CCL4, and CCL5 dose dependently inhibited BzATP-stimulated release of IL-1β, whereas CXCL16
was ineﬀective. The eﬀect of CCL3 was conﬁrmed for primary mononuclear leukocytes. It was blunted after silencing CCR1 or
calcium-independent phospholipase A2 (iPLA2) by siRNA and was sensitive to antagonists of nicotinic acetylcholine receptors
containing subunits α7 and α9. U937 cells secreted small factors in response to CCL3 that mediated the inhibition of IL-1β
release. We suggest that CCL chemokines inhibit ATP-induced release of IL-1β from U937 cells by a triple-membrane-passing
mechanism involving CCR, iPLA2, release of small mediators, and nicotinic acetylcholine receptor subunits α7 and α9. We
speculate that whenever chemokines and ATP enter the circulation concomitantly, systemic release of IL-1β is minimized.
1. Introduction
The orchestration of inﬂammation in response to tissue
injury is essential for patient survival. Trauma-associated
inﬂammation is a complex process involving release of
danger-associated molecular patterns (DAMP), cell signal-
ing, production and secretion of inﬂammatory mediators,
local regulation of barrier functions, and recruitment of
inﬂammatory cells [1–3]. Recruited leukocytes are essential
for the elimination of cellular debris and foreign matter, for
the prevention of infections, and for the initiation of tissue
regeneration [1–3]. The site of inﬂammation should, how-
ever, communicate with the immune system with utmost
caution, as exuberant inﬂammation carries the risk of
inducing systemic inﬂammatory response syndrome (SIRS)
that predisposes to life-threatening complications includ-
ing systemic barrier dysfunction, sepsis, and multiorgan
failure [1–3].
Countless mediators fromwounds or other inﬂammatory
sites enter the circulation via damaged blood vessels. The
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earliest among them is extracellular ATP and chemokines
[4, 5]. Extracellular ATP, mainly originating from the
cytoplasm of injured cells, is a DAMP that upon binding
to receptor P2X7 expressed by primed monocytes/macro-
phages induces the assembly of the NLRP3 (NACHT,
LRR, and PYD domain-containing protein 3) inﬂamma-
some [6–8]. NLRP3 inﬂammasomes activate the protease
caspase-1 that enables maturation and release of
inﬂammasome-dependent cytokines such as IL-1β and IL-
18 [6–8]. IL-1β is a potent proinﬂammatory cytokine, pre-
dominantly but not exclusively produced by monocytes
and macrophages, that plays a central role in host defense
against viral, bacterial, and fungal infections [9]. High
systemic levels of IL-1β, however, can cause severe systemic
inﬂammation resembling SIRS [10]. Inﬂammasome activa-
tion also induces pyroptosis in monocytes/macrophages, a
proinﬂammatory form of programmed cell death [11].
Chemokines are a family of predominantly proinﬂam-
matory peptides produced and released by immune and
diverse nonimmune cells. Some chemokines are constitu-
tively expressed and mainly regulate steady-state traﬃcking
of leukocytes, while the majority are induced by DAMP or
pathogen-associated molecular patterns (PAMP) [12].
Inducible chemokines primarily activate and attract leuko-
cytes to the site of inﬂammation, and the spectrum of diﬀer-
ent chemokines that are released determines the cellular
composition of the inﬁltrate. Each leukocyte subpopulation
expresses a characteristic set of chemokine receptors that
belong to the family of G protein-coupled receptors [13].
Monocytes are mainly mobilized by CC-chemokines that
bind to CC-receptors (CCR), whereas they normally do not
respond to CXC-chemokines as they are lacking their cog-
nate CXC-receptors (CXCR) [12, 14, 15].
When chemokines that attract monocytes enter the cir-
culation together with ATP, we predict a prioritization of
the chemotactic signal that enables cellular inﬁltration of
the inﬂamed tissue but prevents IL-1β release to avoid SIRS.
Hence, monocytes should be attracted to the site of inﬂam-
mation, whereas ATP-induced release of inﬂammasome-
dependent cytokines into the blood stream and premature
pyroptosis of monocytes should be controlled. This predic-
tion prompted us to test the hypothesis that CCR activation
down-modulates ATP-dependent release of IL-1β by lipo-
polysaccharide- (LPS-) primed humanmonocytic U937 cells.
In line with this hypothesis, we demonstrate that chemokines
CCL3 (MIP1α), CCL4 (MIP1β), and CCL5 (RANTES) eﬃ-
ciently inhibit release of IL-1β in response to ATP receptor
stimulation. We provide evidence that the eﬀect of CCL3
is mediated via CCR1 and calcium-independent phospholi-
pase A2 (iPLA2), release of a soluble small mediator and
nicotinic acetylcholine receptors (nAChR) containing sub-
units α7 and α9.
2. Material and Methods
2.1. U937 Cells. The human histiocytic lymphoma cell line
U937 was obtained from the German Collection of Microor-
ganisms and Cell Cultures (Braunschweig, Germany) and
cultured in RPMI 1640 (Gibco by Life Technologies,
Darmstadt, Germany), supplemented with 10% fetal calf
serum (Biochrome, Berlin, Germany), and 2mM L-
glutamine (Gibco), at 37°C,5%CO2.Experimentswere carried
out in 24-well plates containing 106 cells in 1ml. Cells were
primed for 5 h with 1μg/ml LPS from Escherichia coli
(L2654; Sigma-Aldrich, Taufkirchen, Germany) followed by
stimulation with the P2X7 receptor agonist BzATP (2′(3′)-O-
(4-benzoyl-benzoyl) ATP triethylammonium salt (Sigma-
Aldrich or Jena Bioscience, Jena, Germany; 100μM). Cell
culture supernatants were harvested 30min later and stored
at −20°C before detection of IL-1β by Quantikine® Immuno-
assay (R&D Systems, Minneapolis, MN) andmeasurement of
lactate dehydrogenase (LDH) using the CytoTox 96® Non-
Radioactive Cytotoxicity Assay (Promega, Madison, WI).
Diﬀerent concentrations of chemokines CCL3, CCL4,
CCL5, or CXCL16 (R&D Systems; 0.1–50 ng/ml) were
applied together with BzATP, in the presence or absence of
antagonists mecamylamine hydrochloride (100μM; Sigma-
Aldrich), α-bungarotoxin (1μM; Tocris Bioscience, Bristol,
UK), and strychnine hydrochloride (10μM; Sigma-Aldrich)
or of the conotoxins ArIB [V11L,V16D] (500 nM) or RgIA4
(200 nM) [16–19]. To inhibit phospholipase A2 (PLA2),
50μM arachidonyl triﬂuoromethyl ketone (ATK; Enzo Life
Sciences, Lausen, Switzerland) or 50μM bromoenol lactone
(BEL; Enzo Life Sciences) was used. In some experiments,
acetylcholine (Sigma-Aldrich; 10μM) was included as a
positive control.
2.2. Human PBMC. Studies on human blood from male
healthy nonsmoking volunteers were approved by the local
ethics committee of the University of Giessen (number 81/
13). PBMC were freshly isolated from heparinized blood by
Leucosep gradients (Greiner Bio-One, Frickenhausen, Ger-
many). In IL-1β release experiments, cells were pulsed with
0.5 ng LPS/ml before separation and PBMC were cultured
for 3 h in RPMI 1640, 10% FCS, 2mM L-glutamine. Nonad-
herent cells were removed, cell culture medium was replaced,
and BzATP (100μM) was added for 30min in the presence
or absence of CCL3 (10ng/ml). IL-1β and LDH was mea-
sured in cell culture supernatants.
2.3. Gene Silencing.U937 cells were transfected with CCR1 or
PLA2G6 human siRNA ON-TARGETplus SMARTpool (GE
Dharmacon, Lafayette, CO, USA), at a concentration of
30 pmol siRNA per 1 ×106 cells, using the Amaxa® Cell Line
Nucleofector® Kit C from Lonza (Cologne, Germany). ON-
TARGETplus Nontargeting Control Pool (GE, Dharmacon)
was included as a negative control. The cells were incubated
under standard conditions for 48 hours before IL-1β release
studies were performed. The eﬃciency of gene silencing
was analyzed by real-time RT-PCR (CCR1 and PLA2G6)
and Western blotting (iPLA2). The protein expression of
CCR1 by U937 cells was below the threshold of detection in
both Western blotting and ﬂow cytometry.
2.4. RNA Isolation and Real-Time RT-PCR. RNAwas isolated
from untreated and LPS-primed U937 cells as well as from
siRNA-treated U937 cells at the end of the IL-1β release
experiment. Total RNA extracted using the Qiagen RNeasy
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Miniprep Kit (Qiagen, Hilden, Germany) and cDNA was
produced using M-MLV reverse transcriptase (Promega,
Mannheim, Germany). Real-time PCR was performed in an
ABI 7700 Sequence Detection System (PE Applied Biosys-
tems, Foster City, CA) using Platinum SYBR green qPCR
Super Mix-UDG (Invitrogen). The expression of hydroxy-
methylbilane synthase (HMBS; alias porphobilinogen deam-
inase, PBGD) was analyzed for data normalization. All
primers were synthetized by Euroﬁns Genomics (Ebersberg,
Germany). Primer sequences for chemokine receptors are
indicated in Table 1; primers for HMBS were published
before [20]. To validate the primer pairs, RNA from freshly
isolated human peripheral blood mononuclear cells (PBMC)
was included as a positive control. In negative controls, the
cDNA was replaced by water.
PCR products were separated in 1.5% agarose gels
together with GeneRuler™ 100 bp DNA Ladder (Thermo
Fischer Scientiﬁc, Darmstadt, Germany) to assess their size.
To further conﬁrm the identity of the amplicons, DNA bands
were excised from the gel, eluted (MinElute® PCR Puriﬁca-
tion Kit, Qiagen), and sequenced by SeqLab (Göttingen,
Germany). Data were analyzed using the 2ΔCt method, where
ΔCt is the diﬀerence between the Ct of the housekeeping
gene and of the gene of interest, and the mean values of
the siRNA controls were set to one arbitrary unit.
2.5. Conditioned Medium. U937 cells were primed with LPS
in RPMI 1640 as described but in the absence of fetal calf
serum. Thereafter, CCL3 (10ng/ml) was added for 30min
and cell-free cell culture supernatants were ultraﬁltrated
using Amicon® Ultra Centrifugal ﬁlters (Merck Millipore,
Darmstadt, Germany) with a cut-oﬀ of 3 kDa. The eﬃciency
of the ultraﬁltration was controlled by SDS-gel electrophore-
sis followed by silver staining. The low molecular mass frac-
tion was tested in IL-1β release experiments.
2.6. SDS-Gel Electrophoresis andSilver Staining.Diﬀerent frac-
tions of cell culture supernatant were resolved on 15% reduc-
ing SDS-polyacrylamide gels. The gels were stained with the
Silver Stain Plus (Bio-Rad Laboratories, Munich, Germany)
according to themanufacturer’s instructions anddocumented
using a gel imaging system (Intas, Göttingen, Germany).
2.7. Western Blotting. U937 cells were lysed, and proteins
were separated on 10% SDS-polyacrylamide gels and trans-
ferred onto Immobilon polyvinylidene diﬂuoride membranes
(Millipore, Billerica, MA) together with dual color precision
plus protein standards (Bio-Rad, Hercules, CA). Membranes
were blocked with 5% BSA diluted in PBS and incubated with
polyclonal rabbit antibodies to iPLA2 (1 : 5000; Sigma-
Aldrich) or mouse monoclonal antibodies to β-actin
(1 : 50000; Sigma-Aldrich). Bound primary antibodies were
detected with secondary horse radish peroxidase-labeled
antibodies (1 : 5000; Dako, Glostrup, Denmark), lumi-light
substrate (Roche, Mannheim, Germany), and high-
performance chemiluminescence ﬁlms (GE Healthcare Bio-
Sciences, Uppsala, Sweden).
2.8. Statistical Analyses. Results are presented as individual
data points, median, and percentiles 25 and 75. Data were
analyzed by the nonparametric Kruskal-Wallis test followed
by the Mann–Whitney rank sum test using the SPSS software
(Munich, Germany). p values below 0.05 were considered as
statistically signiﬁcant.
3. Results and Discussion
3.1. CCL-Induced Inhibition of IL-1β Release. First experi-
ments were performed to test our hypothesis that CCL che-
mokines that attract monocytes inhibit the ATP-dependent
release of IL-1β by LPS-primed humanmonocytic U937 cells,
whereas CXCL16, a chemokine that does not target mono-
cytes [12], is ineﬀective. U937 cells were primed with LPS
(1μg/ml) for 5 h followed by activation with the P2X7 agonist
BzATP (100μM) for 30min. In line with previous data
[18, 20], LPS alone did not stimulate the release of IL-1β into
the cell culture medium, whereas the consecutive application
of LPS and BzATP induced its release (Figures 1(a), 1(b),
1(c), and 1(d)). In contrast, IL-18 was barely detectable (data
not shown). In line with our hypothesis, the BzATP-induced
release of IL-1β was dose dependently and eﬃciently inhib-
ited by chemokines CCL3, CCL4, and CCL5 (p = 0 029;
n = 4, each), whereas chemokine CXCL16 was ineﬀective
(Figures 1(a), 1(b), 1(c), and 1(d)). When fully inhibitory
concentrations of chemokines CCL3 (10ng/ml), CCL4
(50 ng/ml), and CCL5 (50 ng/ml) were applied to LPS-
primed U937 cells in the absence of BzATP, no IL-1β was
released into the cell culture medium (Figures 1(a), 1(b),
and 1(c)); similarly, 50 ng/ml CXCL16 had no eﬀect
(Figure 1(d)). The IC50 values were in the range of 1–5ng/
ml for CCL3 and CCL4 and about 10 ng/ml for CCL5. These
IC50 values are in the range of the EC50 values typical for the
activation of their cognate receptors. CCL3 was selected for
the following elucidation of the signaling pathway.
Table 1: List of primers used for real-time RT-PCR.
Gene name (accession number) Forward primer 5′-3′ Reverse primer 5′-3′ Amplicon size (bp)
CCR1 (NM_001295.2) GGA CAA AGT CCC TTG GAA CC GGA GTT GCA TCC CCA TAG TC 101
CCR3 (NM_178328.1) ATC CGG GCA AGA ACT TAT CG AGG ATG TGG TAC CAA AGG TCT C 114
CCR5 (NM_000579.3) CTG GCC AGA AGA GCT GAG AC GGG CTC CGA TGT ATA ATA ATT GA 116
CXCR6 (NM_006564.1) GGA ACA AAC TGG CAA AGC AT TGG CTG CTG TCA TTG AAA CT 107
PLA2G6 (NM_003560.2) CAT CCG TAA CCA CCC CAG C CGT TCT CCG CGC AAT TGG 109
CCR1: C-C motif chemokine receptor 1; CCR3: C-C motif chemokine receptor 3; CCR5: C-C motif chemokine receptor 5; CXCR6: C-X-C chemokine receptor
type 6; PLA2G6: phospholipase A2 group VI.
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The properties of cell lines typically diﬀer considerably
from primary cells. To test if the inhibitory eﬀect of CCL3
on BzATP-mediated release of IL-1β also applies to pri-
mary monocytic cells, PBMC from healthy donors were
investigated (Figure 2). Adherent LPS-pulsed PBMC
secreted a small amount of IL-1β (median 344ng/ml,
range 247–468ng/ml; n = 4) within 30min, application of
BzATP (100μM) increased the IL-1β release (median
3.6 pg/ml, range 0.6–9.2 pg/ml; n = 4), and CCL3 signiﬁ-
cantly reduced the release of IL-1β (median 2.2 pg/ml,
range 0.4–4.2 pg/ml; n = 4).
3.2. Cell Viability. LDH concentrations in the cell culture
supernatants of U937 cells and PBMC remained below 4%
and 10%, respectively, of the total LDH of lysed cells, irre-
spective of the experimental setting. Only in experiments
involving transfection of U937 cells with siRNA, up to 7%
LDH release was measured (data not shown).
3.3. Signaling via CCR. Chemokines CCL3, CCL4, and CCL5
are known agonists of chemokine receptors CCR1, CCR3,
and CCR5 [12]. CXCL16 binds to receptor CXCR6 [12].
First, we analyzed by real-time RT-PCR if the mRNA of
these chemokine receptors is expressed by U937 cells. We
were indeed able to detect the mRNA for CCR1, CCR3, and
CCR5, whereas no mRNA for CXCR6 was detected after 45
cycles of ampliﬁcation. In PBMC that were included as a
positive control, the mRNA of all four chemokine receptors
was expressed and no DNA was ampliﬁed in negative
controls. DNA bands of the expected size were detected in
agarose gels (Figure 3(a)), and DNA sequencing conﬁrmed
product identity.
To analyze if CCR are involved in the CCL3-induced
control of IL-1β release, we transfected U937 cells with
siRNA targeting CCR1 gene expression and primed these
cells with LPS. We selected CCR1 for gene silencing because
the mRNA of this receptor seemed to be more abundant in
U937 cell than CCR3 and CCR5 mRNA. Control cells were
transfected with irrelevant control siRNA. In contrast to con-
trol siRNA, siRNA targeting CCR1 signiﬁcantly inhibited the
mRNA expression (p = 0 029, n = 4; Figure 3(b)). Gene
silencing did not change the BzATP-induced release of IL-
1β, and transfection of control siRNA did not impair the
inhibitory eﬀect of CCL3 on IL-1β release (Figure 3(c)).
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Figure 1: CCL chemokines inhibit ATP-induced IL-1β release. (a) Human monocytic U937 cells were primed with LPS (1 μg/ml, 5 h) and
activated with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 μM, 30min). The release of IL-1β to the cell culture
supernatant was measured by ELISA. Chemokines CCL3 (a), CCL4 (b), and CCL5 (c) dose dependently and eﬃciently inhibited the
BzATP-induced release of IL-1β. In contrast, chemokine CXCL16 (d) was ineﬀective. Data are presented as individual data points, bars
indicate median, and whiskers percentiles are 25 and 75; n = 4; ∗p = 0 029, in comparison to cells treated with LPS and BzATP.
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Silencing of CCR1, however, signiﬁcantly (p = 0 008, n = 5,
each) blunted the inhibitory eﬀect of CCL3 (Figure 3(c)).
These results suggest that the anti-inﬂammatory eﬀect of
CCL3 is at least in part mediated by conventional chemokine
receptors. The eﬀect of CCL3 was not fully inhibited by
silencing of CCR1. This observation may be explained by
the fact that siRNA-treatment did not fully abolish the
expression of CCR1 and that apart from CCR1 other chemo-
kine receptors such as CCR3 and CCR5 are involved.
3.4. Involvement of nAChR. Recently, we discovered that
stimulation of nAChR containing subunits α7, α9, and α10
eﬃciently inhibits the BzATP-triggered release of IL-1β by
primary human monocytes and by LPS-primed U937 cells
[18, 20]. This pathway is speciﬁc for ATP-dependent inﬂam-
masome activation as it inhibits the ion channel function of
receptor P2X7. This prompted us to test if CCL3 also inhibits
the ATP-independent IL-1β release induced by the pore-
forming bacterial toxin nigericin (50μM). In this experimen-
tal setting, we added apyrase (0.5U/ml), an enzyme that eﬃ-
ciently cleaves endogenous ATP that might be released by
LPS-primed and nigericin-treated U937 cells. Stimulation
of LPS-primed U937 cells with nigericin/apyrase for 30min
induced IL-1β secretion as described before (Figure 4(a))
[20]. Of note, nigericin-induced secretion of IL-1β was not
reduced by CCL3 (Figure 4(a)). This result is in line with
our assumption that CCL3 triggers a mechanism that is spe-
ciﬁc for ATP-dependent inﬂammasome activation.
In the next set of experiments, we tested the rather pro-
vocative hypothesis that nAChR are involved in CCL3 signal-
ing using a panel of nAChR antagonists that do not induce
the release of IL-1β when applied alone [18, 20]
(Figure 4(b)). The inhibitory eﬀect of CCL3 on BzATP-
induced release of IL-1β by U937 cells was indeed sensitive
to mecamylamine (100 μM; p = 0 001, n = 5 versus n = 9), a
general nAChR antagonist. Similarly, α-bungarotoxin
(1 μM; p = 0 001, n = 5 versus n = 9) and strychnine (10μM;
p = 0 001, n = 5 versus n = 9), reagents that preferentially
antagonize nAChR containing subunits α7 and α9, were eﬃ-
cient (Figure 4(b)). To diﬀerentiate between those subunits,
we made use of α-conotoxins ArIB [V11L,V16D] (500 nM),
speciﬁc for nAChR containing an α7 subunit, and RgIA4
(200 nM), an antagonist of α9α10 nAChR [16–19]. Both α-
conotoxins antagonized the eﬀect of CCL3 (p = 0 003, n = 5
versus n = 9), suggesting that signal transduction involves
nAChR subunits α7 and α9 (Figure 4(b)). These nAChR sub-
units previously have been shown to be expressed by U937
cells and by human monocytes [20, 21].
These results are in line with the idea that chemokine sig-
naling triggers a recently described mechanism involving
activation of metabotropic functions of noncanonical
nAChR containing subunits α7 and α9 that inhibit P2X7 sig-
naling and, consequently, BzATP-induced release of IL-1β
[18, 20]. Of note, the inhibitory eﬀect of acetylcholine
(10μM) was not impaired by silencing of CCR expression
(Figure 3(c)), suggesting that nAChR are acting downstream
of CCR.
3.5. Release of Soluble Factors. We wanted to solve the ques-
tion of how CCR activation links to cholinergic signaling.
As at least some of the eﬀective nicotinic antagonists such
as α-bungarotoxin and the α-conotoxin RgIA4 probably do
not enter the cytoplasm of the target cell due to their size
and hydrophilicity, we assume that relevant nAChR are
localized in the plasma membrane. Hence, we postulated
the involvement of a soluble small nicotinic agonist that is
released to the cell culture medium in response to CCL3.
To test this hypothesis, LPS-primed U937 cells were
stimulated with CCL3, conditioned cell culture medium
was harvested 30min later, and a low molecular weight frac-
tion of this medium devoid of CCL3 was produced by ultra-
ﬁltration (Figure 5(a)). As a control, conditioned medium
was produced in the absence of CCL3, but CCL3 was added
to the cell-free supernatant shortly before ultraﬁltration. In
line with our hypothesis, the ultraﬁltrate of conditioned
medium signiﬁcantly inhibited the BzATP-stimulated
release of IL-1β by LPS-primed U937 cells, whereas the
ultraﬁltrate of the control conditioned medium was ineﬀec-
tive (p = 0 016; n = 4 versus n = 5) (Figure 5(b)). We won-
dered if this small mediator acts as a nicotinic agonist at
nAChR subunits and were indeed able to demonstrate that
the eﬀect of conditioned medium is antagonized by cono-
toxins ArIB [V11L,V16D] and RgIA4 (p = 0 029; n = 4 each)
that are speciﬁc for nAChR subunits α7 and α9, respectively
(Figure 5(b)). These results suggest that CCL3 induces the
secretion of nicotinic agonists by U937 cells.
3.6. Involvement of iPLA2. How does chemokine signaling
translate into the release of a bioactive factor? We reported
recently that phosphocholine and phosphocholine-modiﬁed
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Figure 2: CCL3 inhibits ATP-induced IL-1β release by human
peripheral blood mononuclear cells (PBMC). Blood from healthy
volunteers was pulsed with 0.5 ng LPS/ml before puriﬁcation
of PBMC. PBMC were cultured for 3 h, and 2′(3′)-O-(4-
benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100 μM) was
added for 30min in the presence or absence of CCL3 (10 ng/ml).
IL-1β was measured in cell culture supernatants, and the values
obtained in the supernatants of cells treated with LPS and BzATP
were set to 100%. Data are presented as individual data points,
bars indicate median, and whiskers percentiles are 25 and 75; n = 4.
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macromolecules are nicotinic agonists at noncanonical
nAChR of human and mouse monocytes that control P2X7
receptor [18, 20]. Hence, it is conceivable that the bioactive
factor is a metabolite of membrane phosphatidylcholines.
Calcium-dependent phospholipase A2 (cPLA2) and iPLA2
use phosphatidylcholines as substrate to form arachidonic
acid, a precursor of several lipid mediators, and lysophospha-
tidylcholines, a metabolite that can be further degraded to
glycerophosphocholine, phosphocholine, or lysophosphati-
dic acid and choline [22, 23]. Interestingly, iPLA2 is essential
for the chemotactic response to CCL2/MCP1 [24, 25]. There-
fore, we investigated if PLA2 is involved in CCL3 signaling
using ATK (50μM), an inhibitor of cPLA2 and iPLA2.
ATK enabled BzATP-induced IL-1β release in despite of
the presence of CCL3 (p = 0 029, n = 4; Figure 6(a)). BEL
(50μM), a speciﬁc inhibitor of iPLA2, was also eﬀective, sug-
gesting that iPLA2 plays an essential role (p = 0 029, n = 4;
Figure 6(a)). The relevance of iPLA2 in CCL3 signaling was
further corroborated in experiments, in which iPLA2 expres-
sion was successfully (Figures 6(b), 6(c), and 6(d)) silenced by
transfection of speciﬁc siRNA (p = 0 029, n = 4; Figure 6(e)).
Taken together, these results are in line with the hypothesis
that iPLA2 is involved in CCL3 signaling and might be a
key enzyme for the production of the bioactive soluble
factor(s) that presumably stimulate nAChR.
3.7. Limitations of the Study. This study has several limita-
tions, and certainly, more research is needed to corrobo-
rate the data presented and to substantiate the intriguing
concept that chemokines attracting monocytes inhibit ATP-
mediated inﬂammasome activation. Here, we only investi-
gated chemokines CCL3, CCL4, and CCL5 with a focus on
CCL3. The concept should be conﬁrmed with other relevant
chemokines that also attract monocytes. Further, we used the
monocytic cell line U937 as a model for human blood mono-
cytes in most experiments. These cells were chosen as they
possess the cholinergic control mechanism of IL-1β release
typical for human blood monocytes [18, 20]. U937 cells,
however, secrete very low amounts of IL-1β in response to
ATP in comparison to primary human and mouse cells
[18, 20]. Therefore, we corroborated the inhibitory potential
of CCL3 also for primary human PBMC in vitro. In the
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Figure 3: Signaling via chemokine receptor CCR1. (a) The mRNA expression of chemokine receptors CCR1, CCR3, CCR5, and CXCR6 was
investigated in U937 cells by real-time RT-PCR, and the amplicons were separated by gel electrophoreses together with a base pair (bp) ladder
and detected by GelRed™Nucleic Acid Dye. Peripheral blood mononuclear cells (PBMC) obtained from healthy volunteers served as positive
control. (b, c) U937 cells were transfected with scrambled control siRNA or with siRNA targeting CCR1. These cells were primed with LPS
(1 μg/ml, 5 h) followed by activation with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate (BzATP) (100 μM, 30min). (b) The
eﬃciency of the siRNA transfection was veriﬁed by real-time RT-PCR. Values obtained for cells treated with siRNA targeting CCR1 were
statistically compared to those transfected with control siRNA. (c) IL-1β was measured in the cell culture supernatant by ELISA. In
untreated and in control-transfected cells, CCL3 (10 ng/ml) fully inhibited the BzATP-induced release of IL-1β, whereas silencing of CCR1
signiﬁcantly blunted the inhibitory eﬀect of CCL3. In all experiments, acetylcholine (ACh; 10 μM) was included as a positive control. Data
are presented as individual data points, bars indicate median, and whiskers percentiles are 25 and 75; n = 5.
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same line, the concept should be tested in vivo, which will
be very diﬃcult due to the high redundancy of chemokines
and chemokine receptors [12, 13, 15]. In addition, there are
numerous open questions regarding the details of the pro-
posed novel signal transduction mechanism, including the
identiﬁcation of the bioactive soluble factor(s) activating
nAChR.
3.8. Biological and Clinical Relevance. Inﬂammasome acti-
vation, resulting in the production of inﬂammasome-
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whiskers percentiles are 25 and 75.
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Figure 4: CCL3 signaling involves nicotinic acetylcholine receptors. Human monocytic U937 cells were primed with LPS (1 μg/ml, 5 h) and
activated (a) with the pore-forming bacterial toxin nigericin (50 μM) or (b) with 2′(3′)-O-(4-benzoylbenzoyl)adenosine-5′-triphosphate
(BzATP; 100μM, 30min). The release of IL-1β to the cell culture supernatant was measured by ELISA. (a) Nigericin induced the release
of IL-1β by LPS-primed U937 cells, but the chemokine CCL3 (10 ng/ml) did not impair the nigericin-triggered release of IL-1β (n = 6).
(b) Nicotinic antagonists mecamylamine (Mec; 100μM), α-bungarotoxin (α-Bun; 1μM), and strychnine (Stry; 10μM), as well as
α-conotoxins ArIB [V11L,V16D] (200 nM) and RgIA4 (200 nM), reversed the inhibitory eﬀect of CCL3. Data are presented as individual
data points, bars indicate median, and whiskers percentiles are 25 and 75.
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Figure 6: CCL3 signaling involves calcium-independent phospholipase A2 (iPLA2). Human monocytic U937 cells were primed with LPS
(1 μg/ml, 5 h) and activated 2′(3′)-O-(4-Benzoylbenzoyl)adenosine-5′-triphosphate (BzATP; 100μM, 30min). The release of IL-1β to the
cell culture supernatant was measured by ELISA. (a) CCL3 (10 ng/ml) inhibited the release of IL-1β in response to BzATP. The general
PLA2 inhibitor arachidonyl triﬂuoromethyl ketone (ATK) and the speciﬁc iPLA2 inhibitor bromoenol lactone (BEL) reversed CCL3-
dependent inhibition. (b–e) Expression of iPLA2 by U937 cells was silenced by siRNA (PLA2G6); scrambled siRNA served as control.
Silencing of PLA2G6 expression was eﬃcient as revealed by real-time RT-PCR (b) and by Western blotting (c, d). Data in (b) and (d) are
given as arbitrary units. (c, d) In Western blotting experiments, β-actin served as a loading control, the optical density (OD) of the
immunopositive bands was measured, and the ratio of the OD of iPLA2 and β-actin was formed. (b, d) Values obtained for cells treated
with siRNA targeting CCR1 were statistically compared to those transfected with control siRNA. (e) After treatment with siRNA targeting
PLA2G6 expression, the inhibitory eﬀect of CCL3 on IL-1β release was blunted. In untreated control cells and upon transfection of
control siRNA, CCL3 was eﬀective. Data are presented as individual data points, bars indicate median, and whiskers percentiles are 25 and
75, n = 4, each.
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dependent mediators and monocyte/macrophage pyropto-
sis, is a double-edged sword that is required for host defense
against infections but is associated with the risk of inducing
life-threatening SIRS [1–3, 11]. The beneﬁts and risks of IL-
1β probably depend on the anatomical compartment to
which this mediator is released. Release of monocytic Il-1β
to the blood stream is expected to be of limited use as the
cytokine is swept away from the site of inﬂammation, but
in contrast, the risk of inducing harmful systemic inﬂamma-
tion is high. In this study, we demonstrate that chemokines
block ATP-dependent IL-1β release by blood monocytes, a
mechanism that would prevent systemic inﬂammation. In
contrast, release of IL-1β by inﬂammatory macrophages
within the tissue ﬁghts against local infections and certainly
causes less systemic eﬀects. We expect that IL-1β can be
released to inﬂamed tissue by macrophages in despite of
high local chemokine levels, because pathogens induce
inﬂammasome activation by several ATP-independent
mechanisms that are probably not sensitive to chemokines
[2, 6, 8, 9]. In addition, it might be hypothesized that
chemokines do not inhibit the ATP-dependent IL-1β release
of tissue macrophages, a topic that certainly deserves more
investigation.
4. Conclusions
Our results are in line with the hypothesis that CCL3,
CCL4, and CCL5 inhibit BzATP-induced maturation and
release of IL-1β by LPS-primed monocytic cells. CCL sig-
naling seems to depend on binding to cognate CCR, acti-
vation of iPLA2, and release of soluble agonists of nAChR
containing subunits α7 and α9 that inhibit IL-1β release
(Figure 7). It has been shown before that activation of
monocytic nAChR is a potent way to inhibit ATP-
induced activation of P2X7 receptor, inﬂammasome acti-
vation, and release of IL-1β [18, 20]. The control of
inﬂammasome activation in despite of the presence of
ATP is of outstanding clinical interest. A better under-
standing of the underlying mechanisms might lead to the
development of therapeutic strategies for the prevention
and treatment of inﬂammatory diseases. With all due cau-
tion, we suggest a novel CCL-induced anti-inﬂammatory
triple-membrane-passing signaling pathway inhibiting pre-
mature inﬂammasome activation in monocytes in response
to extracellular ATP.
This mechanism might reduce trauma-induced release of
IL-1β into the circulation and thereby prevent sterile SIRS.
As trauma is often associated with infection, inﬁltrating
monocytes/macrophages and local IL-1β release at the site
of inﬂammation are desirable. As PAMP-induced inﬂamma-
some activation is typically ATP independent [9], local secre-
tion of inﬂammasome-dependent cytokines by inﬁltrating
monocytes/macrophages should be enabled, in despite of
the presence of chemokines.
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